Lung transplantation

The role of azithromycin in the management of patients with bronchiolitis obliterans syndrome

A. M. Fietta, F. Meloni

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Bronchiolitis obliterans syndrome (BOS) is the leading cause of death in lung transplant recipients (LTR). BOS is thought to result from chronic immunologic/inflammatory insults leading to peri-bronchiolar leukocyte infiltration, with a subsequent exuberant tissue re-modelling and fibro-obliteration of the luminal space of the allograft airways. Diagnosis is based on functional criteria and severity is graded on the degree of Forced Expiratory Volume in 1 second (FEV1) impairment. Current strategies to improve pulmonary function once BOS is established have demonstrated little or no impact on disease progression and re-transplantation remains the only therapeutic option. Among the alternative treatments which have been attempted in the last few years, long-term azithromycin treatment seems to be the most promising therapeutic device for BOS treatment. Azithromycin is a macrolide antibiotic, endowed with a broad spectrum of anti-inflammatory/immunomodulatory activities. Long-term oral azithromycin therapy can significantly improve FEV1 in about 42% of patients with established BOS. Moreover, reduced neutrophilia, chemokine release and bacterial exacerbations have been demonstrated. These observations suggest that the drug can down-regulate pulmonary inflammation, even if the precise underlying mechanisms still need to be determined.

Original languageEnglish
Pages (from-to)716-723
Number of pages8
JournalCurrent Medicinal Chemistry
Volume15
Issue number7
DOIs
Publication statusPublished - Mar 2008

Fingerprint

Bronchiolitis Obliterans
Azithromycin
Lung Transplantation
Transplants
Macrolides
Forced Expiratory Volume
Chemokines
Infiltration
Allografts
Anti-Inflammatory Agents
Therapeutics
Tissue
Anti-Bacterial Agents
Lung
Pharmaceutical Preparations
Disease Progression
Cause of Death
Pneumonia
Leukocytes
Down-Regulation

Keywords

  • Azithromycin
  • Bronchiolitis obliterans syndrome
  • Lung transplant
  • Pulmonary inflammation

ASJC Scopus subject areas

  • Organic Chemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Pharmacology

Cite this

Lung transplantation : The role of azithromycin in the management of patients with bronchiolitis obliterans syndrome. / Fietta, A. M.; Meloni, F.

In: Current Medicinal Chemistry, Vol. 15, No. 7, 03.2008, p. 716-723.

Research output: Contribution to journalArticle

@article{a0b7caa581944cc2bbc74e2783673df5,
title = "Lung transplantation: The role of azithromycin in the management of patients with bronchiolitis obliterans syndrome",
abstract = "Bronchiolitis obliterans syndrome (BOS) is the leading cause of death in lung transplant recipients (LTR). BOS is thought to result from chronic immunologic/inflammatory insults leading to peri-bronchiolar leukocyte infiltration, with a subsequent exuberant tissue re-modelling and fibro-obliteration of the luminal space of the allograft airways. Diagnosis is based on functional criteria and severity is graded on the degree of Forced Expiratory Volume in 1 second (FEV1) impairment. Current strategies to improve pulmonary function once BOS is established have demonstrated little or no impact on disease progression and re-transplantation remains the only therapeutic option. Among the alternative treatments which have been attempted in the last few years, long-term azithromycin treatment seems to be the most promising therapeutic device for BOS treatment. Azithromycin is a macrolide antibiotic, endowed with a broad spectrum of anti-inflammatory/immunomodulatory activities. Long-term oral azithromycin therapy can significantly improve FEV1 in about 42{\%} of patients with established BOS. Moreover, reduced neutrophilia, chemokine release and bacterial exacerbations have been demonstrated. These observations suggest that the drug can down-regulate pulmonary inflammation, even if the precise underlying mechanisms still need to be determined.",
keywords = "Azithromycin, Bronchiolitis obliterans syndrome, Lung transplant, Pulmonary inflammation",
author = "Fietta, {A. M.} and F. Meloni",
year = "2008",
month = "3",
doi = "10.2174/092986708783885228",
language = "English",
volume = "15",
pages = "716--723",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

TY - JOUR

T1 - Lung transplantation

T2 - The role of azithromycin in the management of patients with bronchiolitis obliterans syndrome

AU - Fietta, A. M.

AU - Meloni, F.

PY - 2008/3

Y1 - 2008/3

N2 - Bronchiolitis obliterans syndrome (BOS) is the leading cause of death in lung transplant recipients (LTR). BOS is thought to result from chronic immunologic/inflammatory insults leading to peri-bronchiolar leukocyte infiltration, with a subsequent exuberant tissue re-modelling and fibro-obliteration of the luminal space of the allograft airways. Diagnosis is based on functional criteria and severity is graded on the degree of Forced Expiratory Volume in 1 second (FEV1) impairment. Current strategies to improve pulmonary function once BOS is established have demonstrated little or no impact on disease progression and re-transplantation remains the only therapeutic option. Among the alternative treatments which have been attempted in the last few years, long-term azithromycin treatment seems to be the most promising therapeutic device for BOS treatment. Azithromycin is a macrolide antibiotic, endowed with a broad spectrum of anti-inflammatory/immunomodulatory activities. Long-term oral azithromycin therapy can significantly improve FEV1 in about 42% of patients with established BOS. Moreover, reduced neutrophilia, chemokine release and bacterial exacerbations have been demonstrated. These observations suggest that the drug can down-regulate pulmonary inflammation, even if the precise underlying mechanisms still need to be determined.

AB - Bronchiolitis obliterans syndrome (BOS) is the leading cause of death in lung transplant recipients (LTR). BOS is thought to result from chronic immunologic/inflammatory insults leading to peri-bronchiolar leukocyte infiltration, with a subsequent exuberant tissue re-modelling and fibro-obliteration of the luminal space of the allograft airways. Diagnosis is based on functional criteria and severity is graded on the degree of Forced Expiratory Volume in 1 second (FEV1) impairment. Current strategies to improve pulmonary function once BOS is established have demonstrated little or no impact on disease progression and re-transplantation remains the only therapeutic option. Among the alternative treatments which have been attempted in the last few years, long-term azithromycin treatment seems to be the most promising therapeutic device for BOS treatment. Azithromycin is a macrolide antibiotic, endowed with a broad spectrum of anti-inflammatory/immunomodulatory activities. Long-term oral azithromycin therapy can significantly improve FEV1 in about 42% of patients with established BOS. Moreover, reduced neutrophilia, chemokine release and bacterial exacerbations have been demonstrated. These observations suggest that the drug can down-regulate pulmonary inflammation, even if the precise underlying mechanisms still need to be determined.

KW - Azithromycin

KW - Bronchiolitis obliterans syndrome

KW - Lung transplant

KW - Pulmonary inflammation

UR - http://www.scopus.com/inward/record.url?scp=42049122979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42049122979&partnerID=8YFLogxK

U2 - 10.2174/092986708783885228

DO - 10.2174/092986708783885228

M3 - Article

VL - 15

SP - 716

EP - 723

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 7

ER -